Business
WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY
WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMI...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY\n \n \n Canada NewsWire\n \n \n \n \n \n \n CALGARY, AB\n \n and\n \n MOUNTAIN VIEW, Calif.\n \n \n ,\n \n \n March 22, 2023\n \n \n /CNW/ - WILLOW BIOSCIENCES, (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced that they have, together with SUANFARMA's CIPAN manufacturing site, completed the development and manufacturing process in pilot scale for the WILLOW-owned ingredient, Cannabigerol (CBG). The\n \n 36 m\n \n \n 3\n \n scaling-up production batches required for the forthcoming qualification and registration will be completed during 2023.\n \n \n \n \n \n \n \n \n \n \n SUANFARMA' s CIPAN manufacturing site has significant expertise as a CDMO in fermentation and purification technologies under the highest standards of quality.\n \n \n WILLOW BIOSCIENCES is a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients using its FutureGrown\n \n ™\n \n platform.\n \n \n WILLOW'S CBG, the company's first functional ingredient for consumer care and health & wellness applications, is clinically tested to be safe and has been shown to act as a potent antioxidant, anti-inflammatory and anti-microbial.\n \n \n \n After this successful technology transfer, development, and piloting, SUANFARMA and WILLOW BIOSCIENCES plan to broaden the relationship by offering an end-to-end synthetic biology solution and expanding their joint product portfolio. With this alliance, both companies will bring together their existing pharma and biotech capabilities for the production of ingredients, including anti-infectives and other Active Pharmaceutical Ingredients (APIs) and intermediates for Pharma and natural ingre...